利福平致急性肾损伤1例分析

doi:10.19803/j.1672-8629.2022.04.24

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (4): 453-455.
DOI: 10.19803/j.1672-8629.2022.04.24

利福平致急性肾损伤1例分析

任全霞¹, 吴彬², 黄明霞^1,*

¹银川市第一人民医院药学部,宁夏银川 750001;
²广州市第一人民医院药学部,广东广州 510000

收稿日期:2020-05-18 出版日期:2022-04-15 发布日期:2022-04-15
通讯作者: ^*黄明霞,女,本科,副主任药师,临床药学。E-mail：362660043@qq.com
作者简介:任全霞,女,硕士,主管药师,临床药学。
基金资助:
宁夏回族自治区卫生计生委重点研究课题(2018-NW-066)

One case of acute kidney injury induced by rifampicin

REN Quanxia¹, WU Bin², HUANG Mingxia^1,*

¹Department of Pharmacy, the First People's Hospital of Yinchuan, Yinchuan Ningxia 750001, China;
²Department of Pharmacy, the First People's Hospital of Guangzhou, Guangzhou Guangdong 510000, China;

Received:2020-05-18 Online:2022-04-15 Published:2022-04-15

摘要/Abstract

摘要： 目的探讨利福平致急性肾损伤的处置措施。方法分析1例利福平致急性肾损伤患者诊疗经过,结合文献分析,探索利福平诱发急性肾损伤的机制及处理措施。结果患者第2次口服利福平后复查血肌酐值为477.2 μmol·L^-1,立即停药,先后行10次血液透析治疗后,血肌酐值由579.2 μmol·L^-1降至80.6μmol·L^-1。结论利福平导致急性肾损伤时应立即停药,并根据肾功能损伤程度采取相应的治疗措施。

关键词: 利福平, 抗结核病药, 急性肾损伤, 药品不良反应

Abstract: Objective To explore ways in which acute kidney injury induced by rifampicin can be treated. Methods The process of treating one case of rifampicin-induced acute kidney injury was analyzed. The possible pathogenesis and treatments of rifampicin-induced acute kidney injury were discussed based on literature review. Results The serum creatinine was 477.2 mol·L^-1 after the second oral rifampicin. Rifampicin was immediately withdrawn and hemodialysis was performed ten times. The serum level of creatinine decreased from 579.2 mol·L^-1 to 80.6 mol·L^-1. Conclusion Rifampicin should be withdrawn immediately after acute kidney injury, and corresponding treatments should be provided according to the severity of acute kidney injury.

Key words: rifampicin, anti-tuberculous drugs, acute kidney injury, adverse drug reactions

中图分类号:

R994.11R969.3

任全霞, 吴彬, 黄明霞. 利福平致急性肾损伤1例分析[J]. 中国药物警戒, 2022, 19(4): 453-455.

REN Quanxia, WU Bin, HUANG Mingxia. One case of acute kidney injury induced by rifampicin[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 453-455.

参考文献

[1] GUO H, ZHANG L.A case of rifampicin-induced hemolytic anemia complicated with acute renal injury[J]. J Clin Transfus Lab Med(临床输血与检验), 2018, 20(1): 13-14.
[2] CHIBA S, TSUCHIYA K, SAKASHITA H, et al.Rifampicin-induced acute kidney injury during the initial treatment for pulmonary tuberculosis: a case report and literature review[J]. Intern Med, 2013, 52(21): 2457-2460.
[3] LUZZATI R, GIACOMAZZI D, FRANCHI F, et al.Life-threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis[J]. South Med J, 2007, 100(8): 854-856.
[4] FAN QQ, KONG XD, DENG A, et al.Study progress of drug-induced acute kidney injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(3): 164-168.
[5] KDIGO. Clinical practice guideline for acute kidney injury[J]. Official Journal of the International Society of Nephrology, 2012, 2(1): 1-138.
[6] REBECCA B, MATTHEW TJ.Guidelines for classification of acute kidney diseases and disorders[J]. Foothills Medical Centre, 2015, 11: 1-6.
[7] WANG JF.Literature investigation and analysis of drug-induced acute renal injury in China from 2007 to 2014[J]. Clinical Misdiag-nosis and Mistherapy(临床误诊误治), 2014, 27(10): 54-57.
[8] REN CX, Y ZC. Research progress in drug-induced acute kidney injury[J]. Chin J New Drugs Clin Rem(中国新药与临床杂志), 2019, 38(5): 68-69.
[9] QIU CX, YANG CP, JIN HT. Research progress in mechanisms of drug-induced kidney injury[J]. Chinese Journal of Pharmac-ovigilance(中国药物警戒), 2019, 16(11): 688-694.702.
[10] HAN JF, LI L, WU Q, et al.Rifampicin-induced acute renal failure 8 patients with pulmonary tuberculosis and analysis in literature review[J]. Chin J Antituberculosis(中国防痨杂志), 2010, 32(6): 348-350.
[11] KIM JS, KIM KJ, CHOI EY.Minimal change disease related to rifampicin presenting with acute renal failure during treatment for latent tuberculosis infection: a case report[J]. Medicine (Baltimore), 2018, 97( 22): e10556.
[12] CAO Z, GUO L, NIU K, et al.Clinical analysis of rifampicin-induced acute renal failure[J]. Chin J Integrated Traditional and Western Nephrology(中国中西医结合肾病杂志), 2005, 6(2): 102-103.
[13] RONG G, ZHUO HQ.A case of rifampicin-induced acute renal failure[J]. Guangdong Medical Journal(广东医学), 2018, 39(S1): 279.
[14] LI XM, WANG Y, ZHAO MH, et al.Clinico-pathological features and possible pathogenesis of rifampicin-induced acute renal failure[J]. Chin J Intern Med(中华内科杂志), 2001, 40(6): 370-373.
[15] BAI DP, LI L.Reanalysis of the research progress of rifampicin-associated nephropathy[J]. Chin J Mod Drug Appl(中国现代药物应用), 2011, 5(14): 124-126.
[16] ZHANG P, LI SM.Rifampicin-induced severe adverse reactions in literature review[J]. Chin J of Clinical Rational Drug Use(临床合理用药), 2015, 8(7): 91-93.
[17] RISHI K, SERGEY VB, TIBOR N, et al.Rifampicin in nontuberculous mycobacterial infections: acute kidney injury with hemoglobin casts[J]. Case Reports in Nephrology, 2018: 1-5.
[18] MA YJ, ZHANG Q, WU W.Research progress on adverse reactions of anti-tuberculosis drugs[J]. Shandong Med J(山东医药), 2019, 59(32): 111-113.
[19] PALEVSKY PM, ZHANG JH, O'CONNOR TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury[J]. N Engl J Med, 2008, 359(1): 7-20.

利福平致急性肾损伤1例分析

One case of acute kidney injury induced by rifampicin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.